Belsomra What to Expect: Week-by-Week First Month on Suvorexant

How Suvorexant Works and Why the Timeline Matters

Suvorexant blocks orexin-A and orexin-B from binding OX1R and OX2R receptors, the signaling pathway that keeps the brain in an awake state. Unlike benzodiazepines or Z-drugs, it does not broadly suppress the central nervous system. It removes a wake-promoting signal rather than forcing sedation. That mechanistic difference shapes the entire week-by-week experience: sleep arrives more naturally, but the drug needs consistent nightly use to show its full effect on sleep architecture.

The FDA approved suvorexant in August 2014, making it the first approved drug in the DORA class. Prescribing information is available directly on the FDA database.

Orexin System Basics

Orexin neurons fire most actively during waking hours and fall silent during sleep. In people with chronic insomnia, orexin tone may remain elevated at bedtime, preventing the normal transition to sleep. Research published in the journal Sleep confirms that orexin signaling is dysregulated in hyperarousal-type insomnia.

Why Timing of the Dose Is Pharmacologically Critical

Suvorexant reaches peak plasma concentration (Tmax) in roughly 2 hours under fasted conditions. Taking it 30 minutes before your intended sleep time means peak drug levels coincide with the hours of highest intended sleep pressure. The FDA label specifies this 30-minute window explicitly. Eating a high-fat meal before dosing delays Tmax by approximately 1.5 hours and should be avoided on nights you need reliable onset.

Week 1: First Doses and Initial Sleep Changes

Most patients notice a change on the very first night. Sleep onset time shortens for many people within nights 1 through 3. The effect is often described as "falling asleep without fighting it" rather than a heavy sedative knockout.

What the Evidence Shows for Night 1 to 7

The key Phase 3 trial by Herring et al. (Lancet Neurol 2014, N=1,021) randomized adults with chronic insomnia to suvorexant 15 mg or 20 mg (or placebo) nightly for 3 months. Patients receiving suvorexant 20 mg showed a statistically significant reduction in subjective time to sleep onset versus placebo as early as the first night of measurement. The mean reduction in wake after sleep onset (WASO) at month 1 was approximately 28 minutes versus 15 minutes for placebo.

Polysomnography data from the same trial confirmed that REM sleep percentage increased modestly on suvorexant, consistent with the drug's orexin-blocking mechanism. A secondary analysis of the Herring 2014 data showed that REM rebound was not associated with vivid dreaming complaints in the majority of patients.

Common Side Effects in Week 1

Next-day somnolence is the most frequently reported early adverse effect, occurring in roughly 7% of patients at the 20 mg dose in Phase 3. The full adverse-event table from the FDA label lists somnolence, headache, and dizziness as the top three complaints in the first weeks. Most patients find next-day grogginess resolves by week 2 to 3 as the body adjusts to the drug's half-life (mean 12 hours, range 10 to 22 hours).

Practical tip for week 1: allow at least 7 hours in bed after taking suvorexant. Patients who take it and then must wake after only 5 hours report significantly higher next-morning impairment. The FDA label carries a specific warning about morning impairment when fewer than 7 hours remain.

Week 2: Consolidation of Sleep Architecture

By night 8 to 14, most patients report that sleep onset feels more consistent compared to week 1. The "first-night variability" that characterizes many sleep medications tends to smooth out with suvorexant because the drug's mechanism is less susceptible to tolerance development than GABA-A agonists.

Sleep Architecture Improvements

Polysomnographic data from two Phase 3 trials (combined N greater than 1,600 subjects) show that suvorexant increased total sleep time by a mean of 37 minutes versus placebo at week 4. These findings are summarized in the Merck clinical briefing document reviewed by the FDA advisory committee. The improvement came primarily from reduced WASO rather than faster sleep onset, which is the opposite pattern seen with most Z-drugs.

Dose Adequacy Assessment at Week 2

If 10 mg is insufficient after 7 to 10 nights, guidelines support up-titrating to 20 mg. The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for Chronic Insomnia states: "We suggest that clinicians use suvorexant as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults." The guideline gives suvorexant a weak positive recommendation, citing moderate-quality evidence. For patients with hepatic impairment, the 10 mg ceiling applies; no dose increase is appropriate. Pharmacokinetic data supporting hepatic dosing adjustments appear in the FDA label.

Week 3: Residual Side Effects and Tolerance Assessment

Week 3 is when clinicians typically evaluate whether early adverse effects have resolved and whether the patient is achieving the treatment target: a minimum of 6 hours of sleep with reduced nighttime awakenings.

Somnolence Trajectory

In the Herring 2014 trial, the somnolence rate at month 1 (weeks 1 to 4 combined) was 7.0% for suvorexant 20 mg versus 3.0% for placebo. This difference was statistically significant at P<0.05. By month 3, the gap narrowed, suggesting tolerance to the somnolence side effect specifically, without tolerance to the sleep-promoting benefit.

Sleep-Related Behaviors to Watch

Complex sleep behaviors, including sleepwalking and sleep-driving, occur rarely with suvorexant but are reported. The FDA issued a black-box warning in 2019 applying to all approved orexin receptor antagonists, including suvorexant, following serious case reports. Patients should be told to discontinue suvorexant immediately and contact their prescriber if they engage in any behavior while not fully awake. This risk is independent of dose and appears idiosyncratic.

Comparing Suvorexant to Other Sleep Medications at Week 3

Z-drugs such as zolpidem (Ambien) show measurable tolerance to sleep-onset benefit by week 4 in many patients. A Cochrane review of benzodiazepine receptor agonists (N=154 trials) found that subjective sleep quality improvements diminished after 4 weeks of continuous use. Suvorexant's orexin-blocking mechanism does not involve GABA-A receptor downregulation, which is the primary driver of Z-drug tolerance. This difference means week 3 on suvorexant should feel at least as effective as week 1, not less.

Week 4: Evaluating One Full Month of Therapy

By the end of 30 days, both patient and prescriber have enough data to make a shared decision about continuing, adjusting, or switching therapy.

Efficacy Benchmarks at 30 Days

The Herring 2014 trial used two co-primary endpoints: change from baseline in subjective WASO (sWASO) and subjective total sleep time (sTST) at 1 and 3 months. At month 1, suvorexant 20 mg reduced sWASO by 28 minutes (P<0.001 vs. Placebo) and increased sTST by approximately 42 minutes. Patients who did not reach these thresholds by month 1 were less likely to respond at month 3, suggesting the first 30 days represent a clinically meaningful prognostic window.

A second Phase 3 trial (Michelson et al., Sleep 2014) using slightly different dose arms (15 mg and 20 mg in younger adults; 10 mg and 15 mg in patients aged 65 and older) produced consistent results. Michelson et al. Found that suvorexant 15 mg in elderly patients produced significant WASO reduction without the next-day balance impairment seen with higher doses.

Older Adults: Special Considerations at Month 1

For patients 65 and older, the recommended starting dose drops to 5 mg (though 10 mg is the approved labeled starting dose for this group). The American Geriatrics Society Beers Criteria 2023 update does not list suvorexant as a potentially inappropriate medication for older adults, unlike benzodiazepines and Z-drugs, which carry explicit Beers warnings. This distinction makes suvorexant one of the few approved insomnia medications without a Beers flag at standard doses.

Discontinuation at Month 1: What to Expect

Suvorexant does not produce the rebound insomnia spike characteristic of benzodiazepine withdrawal. A pre-specified discontinuation substudy within Herring 2014 found no statistically significant rebound beyond baseline WASO after stopping suvorexant at month 3. If a patient stops at the 30-day mark, they may notice their natural insomnia return, but they should not experience worsened sleep compared to pre-treatment. Patients should taper by halving the dose for 1 week before stopping, per standard clinical practice, even though forced tapering has not been shown to differ significantly from abrupt discontinuation in trial data.

Drug Interactions Relevant to the First Month

Several drug interactions are worth flagging before the first prescription.

CYP3A4 Inhibitors and Inducers

Suvorexant is primarily metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin can double plasma exposure and increase next-day somnolence significantly. The FDA label recommends avoiding suvorexant with strong CYP3A4 inhibitors entirely. Moderate inhibitors such as fluconazole or diltiazem require a dose reduction to 5 mg. Strong inducers such as rifampin reduce suvorexant efficacy substantially and the combination should be avoided.

CNS Depressants and Alcohol

Adding any CNS depressant to suvorexant within the same evening increases the risk of excessive somnolence and respiratory depression in patients with comorbid sleep apnea. The NIH MedlinePlus drug monograph for suvorexant explicitly lists alcohol, opioids, and muscle relaxants as priority interaction categories. Patients should be counseled to avoid alcohol on any night they take suvorexant.

Suvorexant vs. Lemborexant: Choosing Between DORAs in the First Month

Lemborexant (Dayvigo) is the second FDA-approved DORA, approved in 2019. Both drugs block OX1R and OX2R, but lemborexant has a shorter half-life (17 to 19 hours vs. Suvorexant's mean 12 hours), which in theory reduces next-morning residual effects.

Head-to-Head Evidence

The SUNRISE-2 trial (N=900, published in Sleep 2020) directly compared lemborexant 5 mg and 10 mg to placebo over 12 months. SUNRISE-2 did not include a suvorexant active comparator arm, so direct efficacy comparisons between the two DORAs are based on cross-trial analysis only. A 2022 network meta-analysis in Sleep Medicine Reviews placed both agents in the same efficacy tier for WASO reduction, with lemborexant showing marginal advantage in next-day alertness on driving simulator tasks. The network meta-analysis (N=27 RCTs) found that lemborexant 10 mg and suvorexant 20 mg produced statistically indistinguishable WASO reductions vs. Placebo.

For patients starting in their first month, the choice often comes down to insurance coverage. Both are Schedule IV agents. Both require the same 7-hour sleep opportunity warning.

Special Populations During the First Month

Patients With Depression or Anxiety

Suvorexant does not carry an FDA black-box warning for worsening depression or suicidality, unlike some older sedative-hypnotics. A post-hoc analysis of Phase 3 suvorexant data found no statistically significant increase in Columbia Suicide Severity Rating Scale scores versus placebo over 3 months. Patients with comorbid depression should be monitored in the standard fashion, but the mechanism does not suggest a specific depression risk.

Patients With Obstructive Sleep Apnea

The FDA label permits cautious use of suvorexant in patients with mild to moderate OSA, noting that the drug did not significantly worsen apnea-hypopnea index in a dedicated study. A dedicated polysomnographic trial in OSA patients (N=62) found that suvorexant 40 mg, which is twice the maximum approved dose, did not worsen mean AHI versus placebo. At the approved 10 to 20 mg range, respiratory effects appear minimal in mild-to-moderate OSA.

Pediatric and Adolescent Patients

Suvorexant is approved only for adults aged 18 and older. The FDA label states that safety and efficacy in patients under 18 have not been established. Off-label use in adolescents with delayed sleep-wake phase disorder has been reported in case series but lacks controlled trial support.

Monitoring Plan for the First 30 Days

A structured follow-up schedule helps identify non-responders, side-effect burden, and dose-adjustment needs before a full month is wasted on a suboptimal regimen.

• Night 1 to 3: Patient self-monitors sleep onset time and any next-morning grogginess using a simple sleep diary (available from the National Sleep Foundation).
• Day 7: Brief telehealth or phone check-in. Confirm dose timing, assess somnolence, and screen for any unusual sleep behaviors.
• Day 14: If 10 mg is not producing at least 30 minutes of improved sleep onset or WASO reduction, up-titrate to 20 mg per FDA labeling. Titration instructions appear in full in the Belsomra prescribing information.
• Day 30: Formal efficacy review. Compare baseline Insomnia Severity Index (ISI) score to current score. The ISI is a validated 7-item tool with a minimum clinically important difference of 6 points, as established in a study of 979 adults with insomnia. A reduction of 6 or more points indicates a meaningful treatment response.

The AASM recommends using a standardized outcome measure such as the ISI or Pittsburgh Sleep Quality Index at every follow-up visit for insomnia pharmacotherapy.

Cognitive and Driving Safety in the First Month

Next-day driving impairment is the most studied functional outcome for insomnia medications. Suvorexant's long half-life (mean 12 hours, some patients up to 22 hours) means drug levels at the time of morning driving may still be pharmacologically active, especially at 20 mg.

A driving simulation study (N=46 healthy adults, crossover design) found that suvorexant 20 mg produced a statistically significant increase in lateral deviation, a measure of lane-keeping, at 9 hours post-dose compared to placebo (P<0.05). The effect was not seen at the 10 mg dose. Patients who take 20 mg and must drive within 9 hours of dosing should be counseled about this risk explicitly. This is not a contraindication, but it requires individualized timing planning.

The FDA drug safety communication for suvorexant issued in 2014 and updated in 2019 recommends that prescribers advise patients not to drive until they know how the drug affects their morning alertness.